

January 11, 2021

The Secretary,  
Listing Department,  
National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
C/1 G Block, Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051

(Scrip Code: THYROCARE)

The Secretary,  
Listing Department,  
BSE Limited  
Phiroze Jeejeeboy Towers  
Dalal Street,  
Mumbai- 400 001

(Scrip Code: 539871)

Dear Sir/Madam,

**Sub: Intimation under Regulation No. 30 & 36 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.**

We would like to make the following announcements and business update for the knowledge of our shareholders, investors, and general public:

1. As reported by us in Q2 and subsequently addressed in our investor conference call, we have seen significant business revival in Q3 of the current financial year, after business activities resumed across all states. The non covid business in particular is showing growth after end of the festive season with our marketing campaigns launched to promote preventive care health packages showing promising results. Generally, Q3 observed to be the least contributing quarter to the annual topline historically, though this year revival of business coupled with our aggressive marketing across all the territories has enabled us to achieve about 34% YOY growth in the Q3.
2. The Covid RTPCR tests continued to contribute in terms of volumes of tests performed in Q3, with our increased capacity at Delhi, enabling us to reduce the TAT in northern regions. We continued to engage with various State Governments, Municipal Corporations, Corporates, for being the one point most cost efficient service providers to their patients, in their fight against COVID-19.

We are pleased to announce our stakeholders, the trust and faith of our clients/ patients that continued to help us to achieve this significant milestone.

The quarterly financial statements for the quarter ended 31 December 2020 are under review by our statutory auditors and we will file our detailed financial release post approval by the audit committee and the board, sooner. Since convening physical general meeting is rendered impossible on account of pandemic Covid-19, we are unable to communicate with our shareholders in an effective manner, as also meet their queries.

Therefore, in terms of the Clauses 30 & 36 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we hereby apprise you and all our shareholders



stakeholders of the above material developments having a bearing on our performance / operations / finance, which information we consider as 'price sensitive' concerning our listed securities.

We request you to kindly take on record the above We are also posting this intimation on our web site too.

For **Thyrocare Technologies Limited**



**Ramjee Dorai**  
**Company Secretary & Compliance Officer**



**Thyrocare Technologies Limited**

📍 D-37/1, TTC MIDC, Turbhe, Navi Mumbai - 400 703, India ☎ 022- 3090 0000 / 4125 2525

✉ enquiry@thyrocare.com 🌐 www.thyrocare.com

(CIN : L85110MH2000PLC123882)